Effects of Tumor Necrosis Factor Alpha Blocker Adalimumab in Experimental Spinal Cord Injury
Journal of Korean Neurosurgical Society
;
: 73-76, 2015.
Article
in English
| WPRIM
| ID: wpr-190410
ABSTRACT
OBJECTIVE:
Tumor necrosis factor alpha (TNF-alpha) have proven effects in pathogenesis of neuroinflammation after spinal cord injury (SCI). Current study is designed to evaluate the effects of an anti-TNF-alpha agent, adalimumab, on spinal cord clip compression injury in rats.METHODS:
Thirty two male adult Wistar rats were divided into four groups (sham, trauma, infliximab, and adalimumab groups) and SCI was introduced using an aneurysm clip. Animals in treatment groups received 5 mg/kg subcutaneous adalimumab and infliximab right after the trauma. Malondialdehyde (MDA) levels were studied in traumatized spinal cord tissues 72 hours after the injury as a marker of lipid peroxidation.RESULTS:
Animals that received anti-TNF-alpha agents are found to have significantly decreased MDA levels. MDA levels were significantly different between the trauma and infliximab groups (p<0.01) and trauma and adalimumab groups (p=0.022). There was no significant difference in neurological evaluation of the rats using Tarlov scale.CONCLUSION:
These results suggest that, like infliximab, adalimumab has favorable effects on lipid peroxidation induced by spinal cord trauma in rats.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Spinal Cord
/
Spinal Cord Injuries
/
Lipid Peroxidation
/
Tumor Necrosis Factor-alpha
/
Rats, Wistar
/
Adalimumab
/
Infliximab
/
Aneurysm
/
Malondialdehyde
Limits:
Animals
/
Humans
/
Male
Language:
English
Journal:
Journal of Korean Neurosurgical Society
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS